Nuriyatul Fhatonah, Ma’sum, Zenith Putri Dewianti, Nur’aini, N. Rusdiana
{"title":"瑞德西韦与鲁索利替尼作为Covid-19支持性管理的有效性:系统评价、meta分析","authors":"Nuriyatul Fhatonah, Ma’sum, Zenith Putri Dewianti, Nur’aini, N. Rusdiana","doi":"10.2991/AHSR.K.210115.114","DOIUrl":null,"url":null,"abstract":"The treatment regimen in severe Covid-19 patients has several types of therapies. However, there is uncertainty about which therapies are more effective in the covid-19 weight category. In June 2020, the study was conducted with keyword search [REMDESIVIR] [RUXOLITINIB] [COVID19] in 2010-2020 using PUBMED.gov. This study used rct (randomization controller trial) method with the theme: the comparison of the effectiveness use of Remdesivir with Ruxolitinib on Covid-19. From the results of the analysis using forest plot obtained, there was a significant difference in the administration of Remdesivir therapy with Ruxolitinib on the improvement from covid-19 on day 7 (1.26 CI 95% 0.41 to 3.86) and day 14 (RR 1.26 CI 95% 0.41 to 3.86). Ruxolitinib therapy is more effective than Remdesivir applied for Covid-19 patients.","PeriodicalId":222657,"journal":{"name":"Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020)","volume":"5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The Effectiveness of Remdesivir versus Ruxolitinib as Covid-19 Supportive Management: Systematic Review, Meta-Analysis\",\"authors\":\"Nuriyatul Fhatonah, Ma’sum, Zenith Putri Dewianti, Nur’aini, N. Rusdiana\",\"doi\":\"10.2991/AHSR.K.210115.114\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The treatment regimen in severe Covid-19 patients has several types of therapies. However, there is uncertainty about which therapies are more effective in the covid-19 weight category. In June 2020, the study was conducted with keyword search [REMDESIVIR] [RUXOLITINIB] [COVID19] in 2010-2020 using PUBMED.gov. This study used rct (randomization controller trial) method with the theme: the comparison of the effectiveness use of Remdesivir with Ruxolitinib on Covid-19. From the results of the analysis using forest plot obtained, there was a significant difference in the administration of Remdesivir therapy with Ruxolitinib on the improvement from covid-19 on day 7 (1.26 CI 95% 0.41 to 3.86) and day 14 (RR 1.26 CI 95% 0.41 to 3.86). Ruxolitinib therapy is more effective than Remdesivir applied for Covid-19 patients.\",\"PeriodicalId\":222657,\"journal\":{\"name\":\"Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020)\",\"volume\":\"5 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2991/AHSR.K.210115.114\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2991/AHSR.K.210115.114","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
Covid-19重症患者的治疗方案有几种类型的疗法。然而，哪种疗法在covid-19体重类别中更有效尚不确定。该研究于2020年6月在PUBMED.gov上检索2010-2020年关键词[REMDESIVIR] [RUXOLITINIB] [covid - 19]进行。本研究采用rct(随机对照试验)方法，主题为:比较Remdesivir与Ruxolitinib治疗Covid-19的疗效。从获得的森林图分析结果来看，在第7天(1.26 CI 95% 0.41 ~ 3.86)和第14天(RR 1.26 CI 95% 0.41 ~ 3.86)，瑞德西韦联合鲁索利替尼治疗对covid-19的改善有显著差异。鲁索利替尼治疗新冠肺炎的效果优于瑞德西韦。
The Effectiveness of Remdesivir versus Ruxolitinib as Covid-19 Supportive Management: Systematic Review, Meta-Analysis
The treatment regimen in severe Covid-19 patients has several types of therapies. However, there is uncertainty about which therapies are more effective in the covid-19 weight category. In June 2020, the study was conducted with keyword search [REMDESIVIR] [RUXOLITINIB] [COVID19] in 2010-2020 using PUBMED.gov. This study used rct (randomization controller trial) method with the theme: the comparison of the effectiveness use of Remdesivir with Ruxolitinib on Covid-19. From the results of the analysis using forest plot obtained, there was a significant difference in the administration of Remdesivir therapy with Ruxolitinib on the improvement from covid-19 on day 7 (1.26 CI 95% 0.41 to 3.86) and day 14 (RR 1.26 CI 95% 0.41 to 3.86). Ruxolitinib therapy is more effective than Remdesivir applied for Covid-19 patients.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
